The Swiss biopharmaceutical company Ferring has bought the Argentine group Massone and its two two production plants. The group was a local API provider for the multi, specializing in assisted fertilization. Ferring will keep on the entire technical staff, while the Uruguayan Federico Gomes de Freitas will take charge of the process of integration.
Several international pharma companies have made headlines in Argentina for their decisions to end their operations in the country. The US drugmaker Eli Lilly left its portfolio in the hands of Argentina’s Raffo, and Swedens’ Diaverum sold its nephrology assets to Olmos.
But here’s a case of a multi moving against the tide. Pharmabiz has learned that Switzerland’s Ferring has acquired the Argentine group Massone from the family of the same name. The group specializes in APIs for assisted fertilization and comprises two companies: Instituto Massone and Biomas. They have production plants are located in the Saavedra neighborhood of Buenos Aires City and in Villa Maipu in the province of Buenos Aires, respectively. See Instituto Massone // See Biomás
According to information received by Pharmabiz, the price paid for the acquisition was close to US$28.5 million. Ferring, which focuses on reproductive health, has used the Massone group as a supplier for years. Founded in 1930, Instituto Massone focuses on research and development for opotherapy, specifically, the production of gonadotropins, used in assisted fertilization procedures.
Ferring’s Reproductive Medicine unit, commanded in Argentina by the Mexican Fabian Garcia Carrillo includes the brands Menopur; Recovelle; Tractocile; and Propess. In 2021, this business had a global turnover of €1.14 billion, representing 54% of the company’s total turnover of €2.1 billion. Massone makes APIs for Menopur and Chorapur/Novarel. See report // Visit website
Ferring has a portfolio comprising products for different specialisms, including gastroenterology and urology. It recently gained FDA approval for the gene therapy Astiladrine as a new treatment for bladder cancer in the US.
